NEW YORK (GenomeWeb News) – Atossa Genetics, which refiled for an initial public offering earlier this year, said in its amended Form S-1 that it net loss for full-year 2011 reached $3.4 million.

In a Form S-1/A filed on Friday with the US Securities and Exchange Commission, the Seattle-based breast cancer diagnostic firm added that it recorded $1,500 in revenues for 2011. For the first quarter of 2012, Atossa posted revenues of $54,713 with a net loss of $1.1 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A survey examines how age, political leanings, and more influence how Americans view certain scientific topics, the Associated Press reports.

A researcher who pleaded guilty to making false statements in research reports has been sentenced to four and a half years in prison and must pay $7.2 million back to the NIH.

The BabySeq project to study the risks and benefits of sequencing newborns is underway.

In Nature this week: association between genome-wide homozygosity and traits like height and cognitive ability, improved CRISPR-Cas9 editing, and more.